Oversubscription of preferential rights issue

The preferential rights issue in AroCell AB (publ) was oversubscribed to 53.8 million Swedish kronor, including subscription rights. This corresponds to a subscription level of approximately 103 percent, of which 76 percent was with preferential rights. This will provide AroCell with approximately 52.2 million Swedish kronor before issue expenses and there will be no need to utilize the guarantee obligations that have been provided.

AroCell CEO Jan Stålemark comments:
It is with honor and satisfaction to receive this confidence from our shareholders. By conducting the plan that we have presented, we will be able to create fundamental proof for how the product performs in different clinical applications. This will provide very good opportunities for the future of the company. In parallel with the clinical validation we will begin marketing and introductory sales of TK 210 ELISA, primarily to customer segments within clinical research and pharmaceutical companies. We have determined that this preferential rights issue will provide us with sufficient resources to conduct the clinical development of TK 210 ELISA, and thereby create significant value as an established in vitro diagnostic company should represent on the large and rapidly growing market for cancer diagnostics.

Subscription and distribution
The preferential rights issue provides new issue of 5 213 546 shares. A total of applications from shareholders corresponded to 53 822 950 Swedish kronor. 3 950 573 shares (approximately 76 percent of the rights issue volume) were distributed among applicants supported by preferential rights. Transfer notes are planned to be distributed on December 8, 2015. AroCell will be provided with approximately 52.2 million Swedish kronor before issue expenses, which are calculated to approximately 3.8 million Swedish kronor and before guarantee expenses which are approximately 3.9 million Swedish kronor.

Shares and share capital
Following the preferential rights issue, the share capital is calculated to 2 867 450.60 Swedish kronor distributed in 28 674 506 shares. Trade with paid subscription shares (Swedish BTA) will continue until the preferential rights issue has been registered by the Swedish Companies Registration Office, which is estimated to take place in mid-January 2016.

Redeye AB are the financial advisors in connection with the preferential rights issue. AroCell AB has also utilized Corpura AB as advisors. Legal advisors to the company is the legal firm of Fredersen Advokatbyrå AB.

For further information:

Jan Stålemark, CEO
AroCell AB (publ)
Tel: 0706-696206
info@arocell.com
www.arocell.com

About AroCell AB (publ)
AroCell AB is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure TK1 protein levels, which provide valuable information about the speed of cell turnover. A tumor has high cell turnover (speed of cell division and cell death) and as a result TK1 can be detected in the blood with a simple laboratory test, called TK 210 ELISA. The test provides valuable clinical information for prognosis and optimization of treatment strategy. The test may also be used for monitoring disease relapse. For more information, please see www.arocell.com . AroCell AB (AROC) is listed at AktieTorget and has about 2 300 shareholders.